title: Clinical efficacy and value of redistributed subclavian arterial infusion chemotherapy for locally advanced breast cancer.
abstract: OBJECTIVE
  The aim of this study was to evaluate the efficacy and safety of redistributed subclavian arterial infusion chemotherapy (RESAIC). We have focused on the local response, quality of life (QOL), and complications. We have also investigated factors that influence the local response of RESAIC.
  
  
  METHODS
  The subjects were patients with locally advanced breast cancer whose tumors were resistant to standard systemic chemotherapy (at least more than two regimens), those who were physically unable to tolerate systemic chemotherapy, and patients with locally recurrent breast cancer. The registration period was between April 2006 and May 2009.
  
  
  RESULTS
  A total of 24 cases in 22 patients (mean age 59.5 years, range 36-82 years) were entered in the study. The local response rate of RESAIC was 77.3% (17/22). The QOL score showed improvement on average. There were no serious complications during catheter port implantation, and there was hematological toxicity over grade 3 in 27.3% (6/22) of patients. A significant difference between responders and nonresponders was seen in patients with a replaced type tumor (on imaging, diffuse contrast enhancement was seen in whole quadrants) (P = 0.043), and the patients underwent radiotherapy (P = 0.043).
  
  
  CONCLUSIONS
  RESAIC is an effective, safe treatment for locally advanced breast cancer. Because it was reviewed in only a few cases, however, large-scale studies are warranted.
authors: Department of Radiology, St. Marianna University School of Medicine, 2-16-1 Sugao, Miyamae-ku, Kawasaki 216-8511, Japan. hshima@auone.jp
authors: Hiroshi
authors: H
authors: Shimamoto
authors: Kenji
authors: K
authors: Takizawa
authors: Yukihisa
authors: Y
authors: Ogawa
authors: Misako
authors: M
authors: Yoshimatsu
authors: Kunihiro
authors: K
authors: Yagihashi
authors: Hiroko
authors: H
authors: Okazaki
authors: Yoshihide
authors: Y
authors: Kanemaki
authors: Yasuo
authors: Y
authors: Nakajima
authors: Tomohiko
authors: T
authors: Ohta
authors: Haruki
authors: H
authors: Ogata
authors: Mamoru
authors: M
authors: Fukuda
references: Anticancer Res. 2003 Sep-Oct;23(5b):4339-45
references: 14666649
references: Jpn J Clin Oncol. 1999 Jan;29(1):23-7
references: 10073147
references: Oncol Rep. 2007 Jan;17(1):253-9
references: 17143506
references: Oncologist. 2005 Oct;10(9):665-85
references: 16249346
references: Cardiovasc Intervent Radiol. 2000 May-Jun;23(3):202-10
references: 10821895
references: Cancer. 1997 Mar 15;79(6):1138-49
references: 9070491
references: Am J Clin Oncol. 1994 Apr;17(2):118-24
references: 7511325
references: J Clin Oncol. 2000 Jun;18(12):2395-405
references: 10856099
references: J Clin Oncol. 2002 Sep 1;20(17):3665-73
references: 12202668
references: Cancer Chemother Pharmacol. 1994;33 Suppl:S142-4
references: 8137476
references: Cancer. 1975 Nov;36(5):1603-12
references: 1192352
references: Eur J Radiol. 2002 Jul;43(1):31-6
references: 12065118
references: In Vivo. 2006 Nov-Dec;20(6A):761-4
references: 17203763
references: Cancer. 1990 Aug 15;66(4):645-50
references: 2386893
references: Radiology. 2004 Mar;230(3):792-802
references: 14739309
references: Ann Oncol. 2007 Dec;18(12):1927-34
references: 17998286
references: J Clin Oncol. 1997 Mar;15(3):974-86
references: 9060536
references: Cardiovasc Intervent Radiol. 2009 Sep;32(5):1059-66
references: 19238484
references: J Clin Oncol. 1993 Mar;11(3):570-9
references: 8445433
references: J Soc Integr Oncol. 2008 Summer;6(3):110-21
references: 19087768
references: Br J Radiol. 2001 Nov;74(887):983-6
references: 11709461
references: Semin Radiat Oncol. 2003 Jul;13(3):176-81
references: 12903007
references: Radiology. 1995 Oct;197(1):199-203
references: 7568824
references: Am J Clin Oncol. 2001 Apr;24(2):185-91
references: 11319296
references: AJR Am J Roentgenol. 2006 Feb;186(2):431-9
references: 16423949